Navigation Links
Long-Term Followup in Phase 3 CLL Trial Shows Genasense(R) is Associated with Significantly Increased Survival in All Responders
Date:5/29/2008

New Data to be Presented at ASCO Shows Survival Benefit in Complete and

Partial Responders Compared with Chemotherapy Alone

BERKELEY HEIGHTS, N.J., May 29 /PRNewswire-FirstCall/ -- Genta Incorporated (OTC Bulletin Board: GNTA) announced the results of long-term followup from a Phase 3 trial of the Company's lead oncology product, Genasense(R) (oblimersen sodium) Injection, in patients with chronic lymphocytic leukemia (CLL). With 5 years of followup, new data show that patients who achieved either a complete response (CR -- the trial's primary endpoint) or a partial response (PR) have also achieved a statistically significant increase in overall survival. The data will be featured in an oral presentation at the annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago on June 2, 2008.

In the Phase 3 trial, 241 patients with relapsed or refractory CLL were randomly assigned to receive chemotherapy with fludarabine plus cyclophosphamide (Flu/Cy) with or without Genasense. This study achieved its primary endpoint, which was a statistically significant increase in the proportion of patients who achieved a complete or nodular partial response (CR) with the addition of Genasense to the Flu/Cy regimen. (17% vs. 7%; P=0.025). In addition, the median duration of CR was also significantly longer for patients treated with Genasense (median not reached but estimated to exceed 36 months vs. 22 months).

Previous analyses showed a significant benefit in overall survival accrued to patients who attained CR. Extended followup has shown that all major responses (CR+PR) achieved with Genasense have now been associated with significantly increased overall survival compared with all major responses achieved with chemotherapy alone (median = 56 months vs. 38 months, respectively). At 5 years, 22 of 49 (45%) responders in the Genasense group remain alive compared with 13 of 54 (24%) responders in the chemotherapy-only group (HR =
'/>"/>

SOURCE Genta Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. New Study Proves That Minimally Invasive Aneurysm Treatment Yields Successful Long-Term Results
2. Cypher(R) Sirolimus-Eluting Coronary Stent Demonstrates Sustained Clinical Benefits Compared to Bare Metal Stents in Five-Year Randomized Clinical Trial With No Differences in Long-Term Safety
3. Sexual Function Affected by Stem Cell Transplant According to Long-Term Study
4. Neupro(R) (Rotigotine Transdermal System) Effective in Controlling Early Morning Motor Impairment and Generally Well-Tolerated for Long-Term Use in Patients with Parkinsons Disease
5. Horizon Therapeutics Initiates Long-Term Phase 3 Safety Study for Lead Product Candidate HZT-501
6. New Analyses of Long-Term LIALDA(TM) (mesalamine) Data Presented at ACG
7. Long-Term 12-Month Safety Data Presented on ADHD Patch DAYTRANA(TM) (methylphenidate transdermal system)
8. Long-Term Data from a Landmark Phase III Trial Show Survival Benefit at Three- and Four-Years in Patients with Glioblastoma multiforme
9. Nabi Biopharmaceuticals Announces Successful Completion of NicVAX(R) Phase 2b Trial; Drug Shows Statistically Significant Rates of Smoking Cessation and Continuous Long-Term Smoking Abstinence at 12 Months
10. Human Genome Sciences Reports Positive Data from Long-Term Treatment with LymphoStat-B(R) in Patients with Active Systemic Lupus Erythematosus
11. Five-Year Data Demonstrate Long-Term Efficacy and Safety with ORENCIA(R) (abatacept) in Adults with Rheumatoid Arthritis Who had an Inadequate Response to Methotrexate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... 2015  PDL BioPharma, Inc. (NASDAQ: PDLI ) ... interest assignment agreement (the "Agreement") in which it has ... ) with up to $200 million in revenue interest ... of Iclusig ® (ponatinib).  Funding of the first ... $50 million each, with the initial amount having already ...
(Date:7/29/2015)... 2015 Touro College has announced that it is ... one of five media marijuana licenses to be issued by ... Health (DOH).  If CanniCare is selected, Touro ... "Our college is supportive of medicinal development and ... Touro College System. "There is still a great deal of ...
(Date:7/29/2015)... MELVILLE, N.Y., July 29, 2015  Henry Schein, ... provider of health care products and services to ... reported record second quarter financial results. ... 2015 were $2.6 billion, an increase of 0.5% ... consisted of 7.5% growth in local currencies and ...
Breaking Medicine Technology:PDL BioPharma Completes Royalty Transaction with ARIAD Pharmaceuticals 2PDL BioPharma Completes Royalty Transaction with ARIAD Pharmaceuticals 3PDL BioPharma Completes Royalty Transaction with ARIAD Pharmaceuticals 4PDL BioPharma Completes Royalty Transaction with ARIAD Pharmaceuticals 5Touro College Announces Support for CanniCare's Medical Cannabis License Application 2Henry Schein Reports Record Second Quarter Results 2Henry Schein Reports Record Second Quarter Results 3Henry Schein Reports Record Second Quarter Results 4Henry Schein Reports Record Second Quarter Results 5Henry Schein Reports Record Second Quarter Results 6Henry Schein Reports Record Second Quarter Results 7Henry Schein Reports Record Second Quarter Results 8Henry Schein Reports Record Second Quarter Results 9Henry Schein Reports Record Second Quarter Results 10Henry Schein Reports Record Second Quarter Results 11Henry Schein Reports Record Second Quarter Results 12Henry Schein Reports Record Second Quarter Results 13Henry Schein Reports Record Second Quarter Results 14Henry Schein Reports Record Second Quarter Results 15Henry Schein Reports Record Second Quarter Results 16Henry Schein Reports Record Second Quarter Results 17Henry Schein Reports Record Second Quarter Results 18Henry Schein Reports Record Second Quarter Results 19Henry Schein Reports Record Second Quarter Results 20Henry Schein Reports Record Second Quarter Results 21Henry Schein Reports Record Second Quarter Results 22Henry Schein Reports Record Second Quarter Results 23Henry Schein Reports Record Second Quarter Results 24Henry Schein Reports Record Second Quarter Results 25
... Immunomedics, Inc. (Nasdaq: IMMU ... monoclonal antibodies to treat cancer and other serious ... 2009 Gastrointestinal Cancers Symposium showed that labetuzumab-SN-38, an ... carcinoma in animal models as an effective new ...
... approach to unblocking heart arteries minimally invasively will mean ... risk overall, particularly for obese patients, according to data ... Endovascular Therapy (ISET). Every year, about one million Americans ... blocked arteries. New data suggests that beginning the angioplasty ...
Cached Medicine Technology:Immunomedics Announces Preclinical Therapy Results of SN-38 Immunoconjugate for Colorectal Cancer 2Immunomedics Announces Preclinical Therapy Results of SN-38 Immunoconjugate for Colorectal Cancer 3Wrist Access Safer, Easier for Many Patients Undergoing Minimally Invasive Treatment of Blocked Heart Arteries 2
(Date:7/29/2015)... ... ... Today marks a significant achievement in bringing new monies into early stage ... by a group of experienced investors, has tapped into an investor community passionate about ... a part of the fund. The Sofia Fund II is now closed to ...
(Date:7/29/2015)... ... ... July is National UV Awareness Month, and in honor of this month, Dr. Melda Isaac ... skin from the sun, as well as how to best treat existing sun damage. Sun ... common skin conditions in America. Many people do not protect their skin sufficiently when going ...
(Date:7/29/2015)... ... 29, 2015 , ... Stealth Therapeutics Inc. announced today that ... the Invisiport at Wheaton Franciscan Healthcare in Milwaukee, Wis. The Invisiport product line, ... patient-friendly alternative to traditional chest ports and peripherally inserted central catheters (PICCs). It ...
(Date:7/29/2015)... Toronto, Canada (PRWEB) , ... July 29, 2015 ... ... described as a “forward thinker.” Since the late 1970s, Dr. Cottrell has been ... His new book, The New Earth, documents many of these prognostications. He warns ...
(Date:7/29/2015)... ... July 29, 2015 , ... HealthPostures ( https://healthpostures.com ... partnership with 247Ergo, an ergonomics specialty firm. Purpose of the partnership is to ... companies undertake could improve worker mobility, functionality and fitness levels. , Executives ...
Breaking Medicine News(10 mins):Health News:Sofia Fund Surpasses Investor Goals 2Health News:July is UV Awareness Month: Learn Top Tips from a Prominent Dermatologist this National UV Awareness Month 2Health News:July is UV Awareness Month: Learn Top Tips from a Prominent Dermatologist this National UV Awareness Month 3Health News:Stealth Therapeutics Inc. Enrolls First Patients in a Clinical Performance Study for the Invisiport Product Line 2Health News:Stealth Therapeutics Inc. Enrolls First Patients in a Clinical Performance Study for the Invisiport Product Line 3Health News:Author Warns Public to Prepare for Imminent Environmental Disaster 2Health News:HealthPostures and 247Ergo Partnership Strengthens America's Wellness 2Health News:HealthPostures and 247Ergo Partnership Strengthens America's Wellness 3
... different types of dementia, but these findings are shocking. We ... study", say researchers Elisabet Englund and Hans Brunnstrm at Lund ... from the cities of Lund and Malm. All of them ... period 1996-2006 and been diagnosed with some form of dementia. ...
... Boston and Google.org have found web-based search data to be ... of outbreaks of dengue, an emerging mosquito-borne virus found in ... capture of disease-related queries in near real time, it could ... affected by dengue respond more quickly to nascent epidemics. ...
... new test that identifies the specific type of tumour they ... at the University of Edinburgh hope this improved diagnosis will ... the most effective drugs. The Edinburgh team worked with ... each of which had a different genetic signature. ...
... Private health clinics across Canada providing weight-loss surgeries are ... and at the expense of quality patient care, according to ... Chaim Bell. "The private clinics in Canada offer ... banding the upper stomach to restrict food intake to patients ...
... Randy Dotinga HealthDay Reporter , MONDAY, May 30 ... are marketed heavily toward children and teens, a leading association ... kids. Young children and teens should avoid energy drinks ... issued Monday, and routine consumption of sports drinks should be ...
... Ill. Functional magnetic resonance imaging (fMRI) may provide ... researchers at Columbia University in New York City, who ... children. Results of their study appear online and in ... is a spectrum disorder characterized by repetitive behaviors and ...
Cached Medicine News:Health News:Difficulties in diagnosing dementia type 2Health News:Searching the web for dengue 2Health News:Targeted testing offers treatment hope for ovarian cancer patients 2Health News:Private weight-loss surgery clinics shedding quality patient care 2Health News:Pediatricians Group Raps Energy and Sports Drinks for Kids 2Health News:Pediatricians Group Raps Energy and Sports Drinks for Kids 3Health News:New research may lead to improved diagnosis of autism 2
SPR treats pigmented and vascular lesions, skin aging, sun damaged skin and fine lines and wrinkles with clinically proven LHE technology....
SkinStation, powered by LHE, is Radiancys flagship product. A powerhouse by design, it incorporates todays most sought after applications all on one user-friendly system ....
Inquire...
Inquire...
Medicine Products: